Centene Corporation
CNC
$67.02
+2.54%
Centene Corporation is a managed care organization that specializes in government-sponsored healthcare programs, primarily administering Medicaid, Medicare, and individual exchange (ACA marketplace) plans, along with Medicare Part D pharmaceutical coverage. As one of the largest players in the government-sponsored managed care space, Centene occupies a distinct niche relative to diversified peers like UnitedHealth and Elevance, with roughly 64% of its 20 million medical members concentrated in Medicaid and about 28% in the individual exchanges, making it highly levered to policy and enrollment dynamics in those programs. The current investor narrative is a turnaround-and-recovery story: after a severe 2025 marked by a massive third-quarter loss and a membership slump that forced voluntary staff buyouts, the company has returned to profitability in 2026, raised guidance, and drawn fresh analyst attention on the back of an attractive forward P/E. The debate now centers on whether operational improvements and cost discipline can offset ACA membership losses and whether non-recurring benefits are flattering otherwise fragile earnings, leaving the stock a battleground between value-oriented bulls and skeptics wary of structural enrollment headwinds.…
CNC
Centene Corporation
$67.02
Related headlines
Investment Opinion: Should I buy CNC Today?
Based on the synthesis of data, the recommendation is a Hold with a bias toward accumulation on weakness. The core thesis is that Centene is a deep-value turnaround play with a forward P/E of 12.22x and a 'buy' consensus (mean rating 2.38), but the revenue decline and earnings quality concerns warrant caution until more evidence of sustainable recovery emerges. The average analyst target of $71.78 implies 9.8% upside, which is modest relative to the risks.
Supporting evidence includes: 1) Revenue growth is negative at -8.96% YoY, but profitability has swung to positive with Q2 2026 net income of $1.091 billion; 2) Free cash flow is robust at $8.968 billion TTM, providing financial flexibility; 3) The valuation is historically low, with PS ratio of 0.10 and P/B of 1.01, well below peers; 4) The implied upside to the average target is 9.8%, but the high target of $85 offers 30% potential. However, the negative trailing net margin (-3.43%) and ROE (-33.44%) highlight the work needed to restore consistent profitability.
The biggest risks that could invalidate the thesis are: 1) Continued ACA membership losses leading to further revenue declines; 2) Margin compression if cost cuts are exhausted; 3) A miss on the aggressive EPS estimate of $9.84. The rating would upgrade to Buy if revenue stabilizes and forward P/E remains below 12x, or downgrade to Sell if membership losses accelerate and operating margins fall below 2%. Relative to its history and peers, CNC appears undervalued on forward earnings, but the discount is justified by structural headwinds; thus, it is fairly valued until the turnaround proves durable.
Sign up to view all
CNC 12-Month Price Forecast
Centene presents a balanced risk-reward profile, with the stock trading at a deep discount on forward earnings but facing significant headwinds from membership losses and margin volatility. The neutral stance reflects that while the turnaround is real, the sustainability of profitability is unproven, and the technical picture shows overextension after a 72.77% one-year rally. The base case (55% probability) targets $70-$73, implying modest upside, while the bear case (20%) could see a drop to $56. Key factors to monitor include Q3 2026 earnings for margin trends and membership stabilization. An upgrade to bullish would require two consecutive quarters of revenue growth and margin expansion above 3.5%; a downgrade to bearish would follow a miss on EPS or a decline in Medicaid enrollment.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $71.78 and implied upside of +7.1% versus the current price.
Average Target
$71.78
0 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$56 - $85
Analyst target range
Centene is covered by 18 analysts, and the consensus leans moderately bullish with a recommendation mean of 2.38 (on a scale where lower is more bullish) and an overall "buy" rating. The average price target is $71.78, which implies approximately +9.8% upside from the current price of $65.36. The sentiment is constructive but not euphoric — recent institutional actions show a mix of upgrades and steady holds, including an Argus Research upgrade to Buy from Hold on August 11, 2026, while firms like JP Morgan, Baird, TD Cowen, Wells Fargo, and RBC Capital maintained Neutral or Hold-equivalent ratings, indicating that the bullish case is gaining traction but remains contested.
The target range spans from a low of $56.00 to a high of $85.00, a wide $29 spread that signals meaningful disagreement about the company's trajectory. The high target of $85.00 implies roughly +30% upside and would require multiple expansion on top of sustained earnings recovery, likely assuming successful cost containment, stabilization of ACA membership, and favorable Medicaid rate updates. The low target of $56.00 implies about -14% downside and prices in continued membership erosion, margin compression, and the possibility that 2026's profitability is flattered by non-recurring benefits. The wide spread, combined with the clustering of Neutral ratings from major banks, suggests analysts see the recovery as real but fragile — conviction is moderate, and the stock's direction will likely hinge on whether upcoming quarters confirm that the operational improvements are structural rather than cyclical.
Bulls vs Bears: CNC Investment Factors
The bull case for Centene rests on a compelling valuation (12.22x forward P/E), a dramatic return to profitability, and robust cash flow generation, supported by a 'buy' consensus and 9.8% upside to the average target. However, the bear case highlights accelerating revenue contraction (-8.96% YoY), concerns about earnings quality due to non-recurring benefits, and technical overextension after a 72.77% one-year rally. Currently, the bear evidence appears slightly stronger because the revenue decline and membership losses are concrete headwinds that could undermine the sustainability of the earnings recovery. The single most important tension is whether the Q2 2026 profitability is structural or merely a temporary rebound from cost cuts; if upcoming quarters show continued margin expansion and revenue stabilization, the bull case will prevail, but if membership losses persist and margins compress, the stock could retest lower levels.
Bullish
- Deep Value on Forward Earnings: CNC trades at a forward P/E of just 12.22x based on estimated EPS of $9.84, a steep discount to the 15-20x range the stock commanded during healthier periods in 2021-2023. The PS ratio of 0.10 and price-to-book of 1.01 are also near multi-year lows, suggesting the market is pricing in substantial skepticism that could reverse if the turnaround holds.
- Dramatic Profitability Reversal: After a catastrophic Q3 2025 loss of $6.631 billion (-13.34% net margin), Centene returned to profitability with Q2 2026 net income of $1.091 billion (2.46% net margin) and operating income of $1.375 billion (3.10% operating margin). This swing demonstrates the effectiveness of cost-cutting measures, including voluntary staff buyouts.
- Robust Free Cash Flow Generation: Despite an 8.96% YoY revenue decline, Centene generated $4.199 billion in free cash flow in Q2 2026 alone, with trailing twelve-month FCF of $8.968 billion. This strong cash generation provides ample liquidity to fund operations and reduce debt, with cash on hand of $24.254 billion.
- Analyst Consensus Leans Bullish: 18 analysts have a consensus recommendation of 'buy' with a mean rating of 2.38, and an average price target of $71.78 implying 9.8% upside from the current $65.36. The high target of $85.00 suggests 30% upside if the recovery accelerates, and recent upgrades like Argus Research's Buy rating on August 11, 2026, indicate growing confidence.
Bearish
- Revenue Contraction Accelerating: Q2 2026 revenue fell 8.96% YoY to $44.375 billion, down from $49.944 billion in Q1 2026 and $49.725 billion in Q4 2025. The sequential decline reflects ACA membership losses that continue to pressure the top line, and the company's heavy Medicaid concentration (64% of members) leaves it vulnerable to policy-driven enrollment shifts.
- Earnings Quality Concerns: The Q2 2026 profitability may be flattered by non-recurring benefits, as suggested by the volatile gross margin, which dropped to 10.40% from 21.90% in Q1 2026. The trailing net margin remains negative at -3.43% and ROE is deeply negative at -33.44%, indicating that the recovery is not yet fully reflected in trailing financials.
- Premium Valuation vs. History: While the forward P/E of 12.22x appears low, it is based on estimated EPS of $9.84 that assumes a full earnings recovery. The stock's PS ratio of 0.10 is near the low end of its historical range (0.32-1.48), but the market may be correctly pricing in structural headwinds, and the PEG ratio of 0.0096 is distorted by negative trailing earnings.
- Technical Overextension Risk: The stock is trading at roughly 89.4% of its 52-week range, just below the high of $69.63, after more than doubling off its low. Short-term momentum has decelerated, with the stock down 2.95% over three months and trailing SPY by 6.08 percentage points, signaling a potential consolidation or reversal.
CNC Technical Analysis
Centene is in a powerful, sustained uptrend that has recovered dramatically from distressed levels. The stock is up 72.77% over the past year and 56.44% year-to-date, trading at $65.36 against a 52-week range of $31.63 to $69.63 — positioning it at roughly 89.4% of its 52-week range, just below the high. This near-high positioning signals strong momentum but also raises the risk of overextension, especially given the stock has more than doubled off its low, meaning late buyers are chasing a move that has already priced in substantial recovery optimism. The 1-year relative strength versus SPY is a striking +56.77 percentage points, confirming CNC has been a decisive market outperformer over the trailing twelve months.
Short-term momentum, however, has decelerated sharply and diverges from the longer-term trend. While the stock is up 2.03% over the past month, it is down 2.95% over the past three months, a stark contrast to the 75.23% six-month gain — indicating the recovery has stalled and entered a consolidation phase. Relative strength tells the same story: CNC trails SPY by 0.09 points over one month and by a meaningful 6.08 points over three months, even as it leads by 60.64 points over six months. This divergence between explosive intermediate gains and recent underperformance suggests the stock is digesting its advance, and the failure to make new highs despite the strong 1-year trend could signal either a healthy pause or the early stages of a trend reversal if support fails.
Key technical levels are well-defined by the 52-week range. Resistance sits at the 52-week high of $69.63 — a breakout above this level would confirm renewed momentum and likely draw trend-following capital, while the 52-week low of $31.63 marks the deep support zone from the 2025 selloff, though intermediate support likely exists near the $60-$62 area where the stock has repeatedly found buyers in recent weeks. With a beta of 1.13, Centene is roughly 13% more volatile than the broader market, a moderate elevation that matters for position sizing — the stock's max drawdown of -32.73% over the period underscores that this is not a low-risk holding, and a breakdown below the recent $60 floor would open the door to a retest of lower levels given the thin support structure beneath.
Beta
1.13
1.13x market volatility
Max Drawdown
-32.7%
Largest decline past year
52-Week Range
$32-$70
Price range past year
Annual Return
+87.4%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +0.9% | +1.8% |
| 3m | -2.5% | +3.5% |
| 6m | +78.2% | +11.2% |
| 1y | +87.4% | +19.1% |
| ytd | +60.4% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory is contracting, a critical concern for the investment case. Second-quarter 2026 revenue came in at $44.375 billion, down 8.96% year-over-year from the prior-year quarter, reflecting the ACA membership losses that have pressured the top line. The multi-quarter trend shows sequential decline from $49.944 billion in Q1 2026 and $49.725 billion in Q4 2025, and the segment mix — Medicaid at $31.97 billion, Medicare at $11.057 billion, Commercial at $9.356 billion, and Other at $1.196 billion — highlights that the company's fortunes remain overwhelmingly tied to Medicaid, where enrollment and rate dynamics are largely policy-driven. The growth trend implies a company in retrenchment rather than expansion, and the investment case now hinges on margin recovery rather than top-line growth.
Profitability has swung back into positive territory after a catastrophic 2025. Q2 2026 net income was $1.091 billion with a net margin of 2.46%, a dramatic reversal from the Q3 2025 loss of $6.631 billion (a -13.34% net margin) and the Q4 2025 loss of $1.1 billion. Gross margin in Q2 2026 was 10.40%, down from 21.90% in Q1 2026 and 15.18% in Q4 2025, though the quarterly gross margin figures are volatile and the Q1 spike appears anomalous relative to the company's historical 9-12% range. The trailing net margin of -3.43% and operating margin of -3.91% reflect the drag of the 2025 losses still embedded in trailing figures, but the sequential return to profitability — with Q2 operating income of $1.375 billion and an operating margin of 3.10% — suggests the cost-cutting measures, including staff buyouts, are bearing fruit.
Balance sheet and cash flow metrics paint a picture of adequate but not fortress-like financial health. The debt-to-equity ratio stands at 0.94, with a current ratio of 1.68 indicating reasonable short-term liquidity, and cash at the end of Q2 2026 was a substantial $24.254 billion. Free cash flow on a trailing twelve-month basis is a robust $8.968 billion, and Q2 2026 alone generated $4.199 billion in FCF on operating cash flow of $4.373 billion, demonstrating strong cash generation despite the revenue decline. However, ROE is deeply negative at -33.44% and ROA is a thin 2.48%, reflecting the lingering impact of 2025's losses on equity; the company's ability to fund itself internally is evident from the FCF, but the elevated debt load and negative trailing returns on equity mean financial risk is moderate and the recovery must be sustained to repair the balance sheet.
Quarterly Revenue
$44.4B
2026-06
Revenue YoY Growth
-9.0%
YoY Comparison
Gross Margin
10.4%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Because Centene's trailing net income is negative (EPS of -$0.33 and trailing P/E of -3.02), the trailing P/E is not meaningful, so the forward P/E is the appropriate primary metric. The forward P/E stands at 12.22x against estimated EPS of $9.84, a modest multiple that reflects the market's expectation of a full earnings recovery in 2026. The gap between the unusable trailing P/E and the 12.22x forward multiple implies the market is pricing in a sharp swing from losses to nearly $10 in per-share earnings, a bet on the durability of the operational turnaround; the PS ratio of 0.10 and EV/Sales of 0.117 are exceptionally low, characteristic of a low-margin, high-volume managed care business.
Relative to the broader healthcare sector, Centene trades at a significant discount on most metrics. The price-to-book ratio of 1.01 and PS ratio of 0.10 are well below what diversified managed care peers typically command, and the forward P/E of 12.22x is at the lower end of the large-cap managed care range, where leaders often trade in the mid-to-high teens. This discount appears partly justified by Centene's inferior profitability — a negative trailing net margin of -3.43% and negative ROE of -33.44% — and its heavy concentration in Medicaid, which carries policy and rate risk. However, if the earnings recovery holds, the discount to peers on forward earnings could narrow, making the valuation a potential source of upside.
Historically, Centene's valuation sits near the low end of its own range. The PS ratio of 0.10 compares to historical quarterly PS readings that ranged from roughly 0.32 to 1.48 over the past several years, and the price-to-book of 1.01 is near the bottom of a historical band that has stretched as high as 1.91. The forward P/E of 12.22x is also below the 15-20x range the stock commanded during healthier periods in 2021-2023. This historically depressed valuation suggests the market is pricing in substantial skepticism about the sustainability of the recovery — presenting either a compelling value opportunity if the turnaround proves durable, or a value trap if membership losses and margin pressure persist.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Centene faces significant financial and operational risks. The company's revenue contracted 8.96% year-over-year in Q2 2026 to $44.375 billion, driven by ACA membership losses, and its heavy concentration in Medicaid (64% of members) exposes it to policy and rate risks. Profitability remains fragile: the trailing net margin is -3.43% and ROE is -33.44%, reflecting the lingering impact of 2025's massive losses. While free cash flow is strong at $8.968 billion TTM, the debt-to-equity ratio of 0.94 and negative trailing earnings indicate that the recovery must be sustained to repair the balance sheet. Additionally, the gross margin fell to 10.40% in Q2 2026 from 21.90% in Q1 2026, highlighting volatility and potential earnings quality issues.
Market and competitive risks are pronounced. Centene operates in a highly regulated industry where government payment rates and enrollment trends are critical; the 2027 Medicare Advantage rate increase provided some relief, but Medicaid redeterminations and ACA subsidy changes could further pressure membership. The stock's beta of 1.13 means it is 13% more volatile than the market, and its max drawdown of -32.73% over the past period underscores the potential for sharp declines. Valuation risk is also a concern: while the forward P/E of 12.22x is low, it relies on estimated EPS of $9.84, and any miss could trigger multiple compression. Analyst sentiment is mixed, with several major banks maintaining Neutral ratings, and the wide target range ($56-$85) signals uncertainty.
The worst-case scenario would involve a continuation of ACA membership losses, margin compression, and the realization that 2026 profitability was largely due to one-time cost cuts. This could lead to a decline toward the 52-week low of $31.63, representing a 51.6% drop from the current price of $65.36. Even a moderate bear case, aligned with the analyst low target of $56.00, implies a 14.3% downside. Given the stock's recent rally and technical overextension, a breakdown below the $60 support level could accelerate selling, potentially testing the $50-$55 range. Investors could lose 14% to 52% in adverse scenarios, making risk management essential.
FAQ
The key risks include: 1) Financial risk: revenue declined 8.96% YoY in Q2 2026, and trailing net margin is -3.43%, indicating ongoing profitability challenges; 2) Operational risk: heavy concentration in Medicaid (64% of members) exposes the company to policy and rate changes, and ACA membership losses have forced staff buyouts; 3) Market risk: the stock has a beta of 1.13 and a max drawdown of -32.73%, making it more volatile than the market; 4) Valuation risk: the forward P/E of 12.22x relies on an EPS estimate of $9.84 that may not be met, and the wide analyst target range ($56-$85) signals uncertainty. These risks are ranked from high to moderate severity.
The 12-month forecast has three scenarios: bull case (25% probability) targets $85.00, assuming successful membership stabilization and EPS delivery; base case (55%) targets $70-$73, assuming gradual improvement and a 12-13x forward P/E; bear case (20%) targets $56.00, assuming continued membership losses and margin compression. The base case is most likely, hinging on Centene meeting its EPS estimate of $9.84 and maintaining a net margin above 2.5%. The average analyst target of $71.78 aligns with the base case, implying 9.8% upside. Key catalysts include Q3 2026 earnings and Medicaid rate updates.
CNC appears undervalued on forward earnings, with a forward P/E of 12.22x compared to the 15-20x range it historically commanded in 2021-2023. The PS ratio of 0.10 and price-to-book of 1.01 are also near multi-year lows, well below peers in managed care. However, this discount is partly justified by negative trailing net margin (-3.43%) and ROE (-33.44%), as well as revenue contraction. The market is pricing in skepticism about the durability of the recovery; if the company meets its EPS estimate of $9.84, the multiple could expand, but any miss could lead to further de-rating. Thus, it is undervalued relative to its own history but fairly valued given current risks.
CNC could be a good buy for value investors willing to accept above-average risk, given its forward P/E of 12.22x and 9.8% upside to the average analyst target of $71.78. The company has returned to profitability with Q2 2026 net income of $1.091 billion and generates strong free cash flow of $8.968 billion TTM. However, revenue is declining (-8.96% YoY) and the sustainability of earnings is uncertain, with trailing net margin at -3.43%. The stock is also technically overextended after a 72.77% one-year rally, trading near its 52-week high. Therefore, it may be suitable for investors with a medium-term horizon who can tolerate volatility, but it is not a low-risk buy at current levels.
CNC is more suitable for a medium-term investment horizon (1-2 years) rather than short-term trading or long-term holding. The stock is in a turnaround phase with high volatility (beta 1.13) and no dividend, making it less ideal for income-focused long-term investors. Short-term trading is risky due to technical overextension and recent momentum deceleration. A suggested minimum holding period of 12-18 months would allow time for the operational improvements to materialize and for the valuation discount to potentially narrow. Investors should monitor quarterly earnings and policy changes closely, as the thesis could shift rapidly.